About Stoke Therapeutics

Stoke is developing antisense oligonucleotide medicines that target RNA splicing to increase gene expression for the treatment of severe genetic diseases.

Repeat Founder
Company Highlights
Year Founded

2017

icon-altEmployees

129

Location (HQ)

USA

Since Last Funding

5 months

Monthly Website Visitors

7.9K

icon-altTotal Investment Amt

$400M

Last Funding Round

Post Ipo Equity

icon-altMoM Headcount Growth

1.57%

icon-altYoY Headcount Growth

8.4%

Key Metrics

Senior Hires

NameLinkedin ProfilePositionDate Joined
John Doehttps://www.linkedin.com/in/johndoeCEOCEO
Jane Doehttps://www.linkedin.com/in/janedoeCTOCTO
John Smithhttps://www.linkedin.com/in/johnsmithCFOCFO
Jane Smithhttps://www.linkedin.com/in/janesmithCOOCOO
Get API access to complete private company database with growth metrics from 15 sources

Similar Companies

Health Care

Biotechnology

Biotechnology Research

Therapeutics

Pharmaceutical